hepatitis b/headache

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 96 rezilta yo

Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To review long-term safety data from the rollover study ETV-901, focusing on adverse events (AEs) with a potential nucleos(t)ide association. METHODS The open-label study ETV-901 (AI463901) assessed the safety of entecavir in chronic hepatitis B patients who received entecavir, lamivudine

Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To study safety and immunogenicity of concomitant administration of hepatitis B (HB), Tetanus-diphtheria (Td), and Measles-mumps-rubella (MMR) vaccines in healthy 11-12-year-olds. METHODS One hundred ninety-seven healthy 11-12-year-olds from the general community were randomized in an

Immunologic effects on peripheral lymphoid cells from patients with chronic hepatitis type B during administration of recombinant interleukin 2.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Nine patients with chronic hepatitis type B were treated with recombinant interleukin 2 (rIL-2). Side effects were limited to low-grade fever and headache, which were transient and tolerable for the patients. Seven normal volunteers and nine patients with chronic active hepatitis were administered

Schistosomiasis japonicum diagnosed on liver biopsy in a patient with hepatitis B co-infection: a case report.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Chronic hepatitis B virus and schistosomiasis are independently associated with significant mortality and morbidity worldwide. Despite much geographic overlap between these conditions and no reason why co-infection should not exist, we present what is, to the best of our knowledge, the

Clinical evaluation of a yeast recombinant hepatitis B vaccine in healthy hospital staff in Singapore.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A yeast recombinant hepatitis B vaccine (subtype adw), derived from purification of HBsAg particles, expressed in the yeast Saccharomyces cerevisiae which contained the gene for HBsAg, was evaluated in 31 healthy adult hospital staff members in Singapore. Each subject received a 10 mcg dose of

Human plasma derived hepatitis B vaccine: Kenyan experience.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To determine the efficacy and safety of hepaccine B. METHODS Vaccination on first-come-first-served basis. METHODS Kenya Medical Research Institute (KEMRI) staff and families at Nairobi, Kenya. METHODS A total of 107 vaccinees aged 0-10 years and 10 years and above. RESULTS Antibody to

Comparison of a triple antigen and a single antigen recombinant vaccine for adult hepatitis B vaccination.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hepatitis B and its sequelae are a major public health problem. Vaccines have been available for almost 20 years; however the disease still remains a global problem. Many factors contribute to the failure to control hepatitis B, including the limited nature of the vaccination programs implemented

Telbivudine for the management of chronic hepatitis B virus infection.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Telbivudine (LdT) is an L-nucleoside that is structurally related to lamivudine. It is highly selective for hepatitis B virus (HBV) and inhibits viral DNA synthesis. LdT was approved by the US Food and Drug Administration on October 25, 2006, for the treatment of chronic HBV infection in

[A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Entecavir (Baraclude®) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor which prevents the HBV from multiplying. Most common adverse reactions caused by entecavir are headache, fatigue, dizziness, and nausea. Until now, there has been no report

Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Antiviral treatment is currently not recommended for patients with chronic hepatitis B with a low viral load. However, they might benefit from acquiring a functional cure (hepatitis B surface antigen [HBsAg] loss with or without formation of antibodies against hepatitis B surface antigen

Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Nucleotide/nucleoside analogues (antiviral therapy) are used in the therapy of HBeAg positive and HBeAg negative chronic hepatitis B. We analyzed ten selected randomized controlled with 2557 patients to estimate the effect of antiviral drugs in chronic hepatitis B with compared to placebo.

Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Aggressive administration of hepatitis B immune globulin (HBIg) has been shown to prevent hepatitis B viral (HBV) infection of the allograft; however, the clinical sequela of such therapy has not been previously described. We reviewed our experience with high dose, intravenous infusion of an

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The nasal vaccine candidate (NASVAC), comprising hepatitis B virus (HBV) surface (HBsAg) and core antigens (HBcAg), has been shown to be highly immunogenic in animal models. METHODS A phase I double-blinded, placebo-controlled randomized clinical trial was carried out in 19 healthy male

Hepatotoxicity and hematologic complications induced by fusidic acid in a patient with hepatitis B cirrhosis: A case report.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Fusidic acid (FA) is an active agent against gram-positive bacteria such as Staphylococcus, it is generally well tolerated and the major adverse effects are mild gastrointestinal discomfort, diarrhea, and headache. However, some rare side effects such as granulocytopenia and

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To assess the clinical effectiveness and cost-effectiveness of adefovirdipivoxil (ADV) and pegylated interferon alfa-2a (PEG) for the treatment of adults with chronic hepatitis B infection (CHB). METHODS Electronic databases for the period from 1995-6 to April 2005. Websites of the

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye